These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36745682)

  • 1. Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection.
    Tang AT; Buchholz DW; Szigety KM; Imbiakha B; Gao S; Frankfurter M; Wang M; Yang J; Hewins P; Mericko-Ishizuka P; Leu NA; Sterling S; Monreal IA; Sahler J; August A; Zhu X; Jurado KA; Xu M; Morrisey EE; Millar SE; Aguilar HC; Kahn ML
    PLoS Biol; 2023 Feb; 21(2):e3001989. PubMed ID: 36745682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 infection of olfactory epithelial cells and neurons drives acute lung injury and lethal COVID-19 in mice.
    Tang AT; Buchholz DW; Szigety KM; Imbhiaka B; Gao S; Frankfurter M; Wang M; Yang J; Hewins P; Mericko-Ishizuka P; Adrian Leu N; Sterling S; Monreal IA; Sahler J; August A; Zhu X; Jurado KA; Xu M; Morrisey EE; Millar SE; Aguilar HC; Kahn ML
    bioRxiv; 2021 Dec; ():. PubMed ID: 34909769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant.
    Cianfarini C; Hassler L; Wysocki J; Hassan A; Nicolaescu V; Elli D; Gula H; Ibrahim AM; Randall G; Henkin J; Batlle D
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human ACE2 protein is a molecular switch controlling the mode of SARS-CoV-2 transmission.
    Yang CF; Liao CC; Hsu HW; Liang JJ; Chang CS; Ko HY; Chang RH; Tang WC; Chang MH; Wang IH; Lin YL
    J Biomed Sci; 2023 Oct; 30(1):87. PubMed ID: 37828601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a humanized mAce2 and a conditional hACE2 mouse models permissive to SARS-COV-2 infection.
    Song IW; Washington M; Leynes C; Hsu J; Rayavara K; Bae Y; Haelterman N; Chen Y; Jiang MM; Drelich A; Tat V; Lanza DG; Lorenzo I; Heaney JD; Tseng CK; Lee B; Marom R
    Mamm Genome; 2024 Jun; 35(2):113-121. PubMed ID: 38488938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.
    Rathnasinghe R; Strohmeier S; Amanat F; Gillespie VL; Krammer F; García-Sastre A; Coughlan L; Schotsaert M; Uccellini MB
    Emerg Microbes Infect; 2020 Dec; 9(1):2433-2445. PubMed ID: 33073694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2.
    Golden JW; Li R; Cline CR; Zeng X; Mucker EM; Fuentes-Lao AJ; Spik KW; Williams JA; Twenhafel N; Davis N; Moore JL; Stevens S; Blue E; Garrison AR; Larson DD; Stewart R; Kunzler M; Liu Y; Wang Z; Hooper JW
    mBio; 2022 Feb; 13(1):e0290621. PubMed ID: 35073750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits.
    Kim SH; Kim J; Jang JY; Noh H; Park J; Jeong H; Jeon D; Uhm C; Oh H; Cho K; Jeon Y; On D; Yoon S; Lim SY; Kim SP; Lee YW; Jang HJ; Park IH; Oh J; Seo JS; Kim JJ; Seok SH; Lee YJ; Hong SM; An SH; Kim SY; Kim YB; Hwang JY; Lee HJ; Kim HB; Choi KS; Park JW; Seo JY; Yun JW; Shin JS; Lee HY; Kim K; Lee D; Lee H; Nam KT; Seong JK
    Front Immunol; 2022; 13():1055811. PubMed ID: 36457995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human ACE2 Polymorphisms from Different Human Populations Modulate SARS-CoV-2 Infection.
    Hu P; Bauer VL; Sawyer SL; Diaz-Griffero F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
    Zhang S; Liu Y; Wang X; Yang L; Li H; Wang Y; Liu M; Zhao X; Xie Y; Yang Y; Zhang S; Fan Z; Dong J; Yuan Z; Ding Z; Zhang Y; Hu L
    J Hematol Oncol; 2020 Sep; 13(1):120. PubMed ID: 32887634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging on ACE2-dependent transocular infection of coronavirus.
    Li D; Xiong L; Pan G; Wang T; Li R; Zhu L; Tong Q; Yang Q; Peng Y; Zuo C; Wang C; Li X
    J Med Virol; 2022 Oct; 94(10):4878-4889. PubMed ID: 35754185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice.
    Su P; Zhai D; Wong AHC; Liu F
    Mol Brain; 2022 Aug; 15(1):71. PubMed ID: 35945596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Bao L; Deng W; Huang B; Gao H; Liu J; Ren L; Wei Q; Yu P; Xu Y; Qi F; Qu Y; Li F; Lv Q; Wang W; Xue J; Gong S; Liu M; Wang G; Wang S; Song Z; Zhao L; Liu P; Zhao L; Ye F; Wang H; Zhou W; Zhu N; Zhen W; Yu H; Zhang X; Guo L; Chen L; Wang C; Wang Y; Wang X; Xiao Y; Sun Q; Liu H; Zhu F; Ma C; Yan L; Yang M; Han J; Xu W; Tan W; Peng X; Jin Q; Wu G; Qin C
    Nature; 2020 Jul; 583(7818):830-833. PubMed ID: 32380511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
    Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
    J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
    Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.
    Davidson AM; Wysocki J; Batlle D
    Hypertension; 2020 Nov; 76(5):1339-1349. PubMed ID: 32851855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.